Point72 Europe (London) LLP Blueprint Medicines Corp Transaction History
Point72 Europe (London) LLP
- $1.62 Billion
- Q4 2024
A detailed history of Point72 Europe (London) LLP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Point72 Europe (London) LLP holds 43,568 shares of BPMC stock, worth $4.15 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
43,568Holding current value
$4.15 Million% of portfolio
0.23%Shares
2 transactions
Others Institutions Holding BPMC
# of Institutions
379Shares Held
61.6MCall Options Held
1.6MPut Options Held
1.41M-
Vanguard Group Inc Valley Forge, PA6.77MShares$645 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$633 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$541 Million0.06% of portfolio
-
State Street Corp Boston, MA2.5MShares$238 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.94MShares$185 Million0.44% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.69B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...